Arcutis Biotherapeutics, Inc.

Symbol: ARQT




Market price today

  • -3.1617

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 1.03B

    MRK Cap

  • 0.00%

    DIV Yield

Arcutis Biotherapeutics, Inc. (ARQT) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Todd Franklin Watanabe M.A.
Full-time employees:296
City:Westlake Village
Address:3027 Townsgate Road

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

General Outlook

In simple terms, Arcutis Biotherapeutics, Inc. has 114.971 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.913% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -4.045%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -4.392%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.767% return, is a testament to Arcutis Biotherapeutics, Inc.'s adeptness in optimizing resource deployment. Arcutis Biotherapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.944%. Furthermore, the proficiency of Arcutis Biotherapeutics, Inc. in capital utilization is underscored by a remarkable -0.818% return on capital employed.

Stock Prices

Arcutis Biotherapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10, while its low point bottomed out at $9.16. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Arcutis Biotherapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing ARQT liquidity ratios reveals its financial health of the firm. The current ratio of 708.05% gauges short-term asset coverage for liabilities. The quick ratio (639.82%) assesses immediate liquidity, while the cash ratio (191.40%) indicates cash reserves.

Current Ratio708.05%
Quick Ratio639.82%
Cash Ratio191.40%

Profitability Ratios

ARQT profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -434.67% underscores its earnings before tax deductions. The effective tax rate stands at -4.93%, revealing its tax efficiency. The net income per EBT, 101.04%, and the EBT per EBIT, 107.46%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -404.49%, we grasp its operational profitability.

Pretax Profit Margin-434.67%
Effective Tax Rate-4.93%
Net Income per EBT101.04%
EBT per EBIT107.46%
EBIT per Revenue-404.49%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 7.08, it details the span from stock purchase to revenue. The 6 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 230.97% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding640
Days of Inventory Outstanding925
Operating Cycle1082.60
Days of Payables Outstanding844
Cash Conversion Cycle238
Receivables Turnover2.31
Payables Turnover0.43
Inventory Turnover0.39
Fixed Asset Turnover15.28
Asset Turnover0.17

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.67, and free cash flow per share, -2.67, depict cash generation on a per-share basis. The cash per share value, 2.95, showcases liquidity position. Lastly, the operating cash flow sales ratio, -4.14, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-2.67
Free Cash Flow per Share-2.67
Cash per Share2.95
Operating Cash Flow Sales Ratio-4.14
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-1.22
Short Term Coverage Ratio-336.13
Capital Expenditure Coverage Ratio-577.24
Dividend Paid and Capex Coverage Ratio-577.24

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 59.33%, highlights its total liabilities relative to assets. With a debt-equity ratio of 2.28, we discern the balance between debt and equity financing. The long-term debt to capitalization, 69.47%, and total debt to capitalization, 69.55%, ratios shed light on its capital structure. An interest coverage of -8.11 indicates its ability to manage interest expenses.

Debt Ratio59.33%
Debt Equity Ratio2.28
Long Term Debt to Capitalization69.47%
Total Debt to Capitalization69.55%
Interest Coverage-8.11
Cash Flow to Debt Ratio-1.22
Company Equity Multiplier3.85

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.86, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.78, reflects the portion of profit attributed to each share. The book value per share, 1.28, represents the net asset value distributed per share, while the tangible book value per share, 1.19, excludes intangible assets.

Revenue Per Share0.86
Net Income Per Share-3.78
Book Value Per Share1.28
Tangible Book Value Per Share1.19
Shareholders Equity Per Share1.28
Interest Debt Per Share3.35
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 1517.09%, indicates top-line expansion, while the gross profit growth, 1724.28%, reveals profitability trends. EBIT growth, 20.07%, and operating income growth, 20.07%, offer insights into operational profitability progression. The net income growth, 18.41%, showcases bottom-line expansion, and the EPS growth, 35.27%, measures the growth in earnings per share.

Revenue Growth1517.09%
Gross Profit Growth1724.28%
EBIT Growth20.07%
Operating Income Growth20.07%
Net Income Growth18.41%
EPS Growth35.27%
EPS Diluted Growth35.27%
Weighted Average Shares Growth25.94%
Weighted Average Shares Diluted Growth25.94%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth4.14%
Free Cash Flow Growth11.93%
10-Year Operating CF Growth per Share-1603.10%
5-Year Operating CF Growth per Share-356.46%
3-Year Operating CF Growth per Share-12.49%
10-Year Net Income Growth per Share-1270.37%
5-Year Net Income Growth per Share-254.28%
3-Year Net Income Growth per Share0.57%
10-Year Shareholders Equity Growth per Share562.13%
5-Year Shareholders Equity Growth per Share196.19%
3-Year Shareholders Equity Growth per Share-83.14%
Receivables Growth205.12%
Inventory Growth74.79%
Asset Growth-24.02%
Book Value per Share Growth-66.41%
Debt Growth1.67%
R&D Expense Growth-39.39%
SGA Expenses Growth50.68%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 340,449,723.01, captures the company's total value, considering both debt and equity. Income quality, 0.94, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 1.89%, indicates the value of non-physical assets, and capex to operating cash flow, 0.17%, measures reinvestment capability.

Enterprise Value340,449,723.01
Income Quality0.94
Research and Development to Revenue185.51%
Intangibles to Total Assets1.89%
Capex to Operating Cash Flow0.17%
Capex to Revenue-0.72%
Capex to Depreciation-22.75%
Stock-Based Compensation to Revenue65.12%
Graham Number10.43
Return on Tangible Assets-78.27%
Graham Net Net0.66
Working Capital283,763,000
Tangible Asset Value82,229,000
Net Current Asset Value77,733,000
Invested Capital2
Average Receivables17,132,500
Average Payables10,409,500
Average Inventory10,324,000
Days Sales Outstanding158
Days Payables Outstanding715
Days of Inventory On Hand784

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 9.33, and the price to book ratio, 9.33, reflect the market's valuation relative to the company's book value. The price to sales ratio, 17.24, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -4.15, and price to operating cash flows, -3.35, gauge market valuation against cash flow metrics.

Price Book Value Ratio9.33
Price to Book Ratio9.33
Price to Sales Ratio17.24
Price Cash Flow Ratio-3.35
Enterprise Value Multiple-3.93
Price Fair Value9.33
Price to Operating Cash Flow Ratio-3.35
Price to Free Cash Flows Ratio-4.15
Price to Tangible Book Ratio2.52
Enterprise Value to Sales5.71
Enterprise Value Over EBITDA-1.42
EV to Operating Cash Flow-1.38
Earnings Yield-117.10%
Free Cash Flow Yield-110.56%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Arcutis Biotherapeutics, Inc. (ARQT) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.162 in 2024.

What is the ticker symbol of Arcutis Biotherapeutics, Inc. stock?

The ticker symbol of Arcutis Biotherapeutics, Inc. stock is ARQT.

What is company IPO date?

IPO date of Arcutis Biotherapeutics, Inc. is 2020-01-31.

What is company current share price?

Current share price is 8.940 USD.

What is stock market cap today?

The market cap of stock today is 1027840740.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 296.